Humana Star Ratings: Why 95% Isn't a Profit Forecast

Humana received encouraging news last week. The health insurer announced that 95% of its Medicare Advantage members are enrolled in plans rated four stars or higher for 2027 by the Centers for Medicare & Medicaid Services (CMS). The improvement strengthens Humana's position in a quality-based payment system that can materially influence the economics of its insurance business.

The announcement was particularly important because higher-rated plans can qualify for additional government payments. Investors therefore have a clear reason to care about the result. However, the financial benefits associated with the newly announced ratings primarily relate to 2028, and the amount of additional revenue that ultimately becomes profit will depend on several factors that remain uncertain.

This creates an interesting investment lesson. An operating indicator can improve dramatically before the corresponding financial benefits appear in reported earnings. Even when the improvement is genuine, investors still need to understand how it translates into economic value.

What changed at Humana?

On October 9, Humana announced the results of its 2027 Medicare Advantage Star Ratings. According to the company's official announcement, 95% of its Medicare Advantage members are enrolled in plans rated at least four stars, while 42% are enrolled in plans rated 4.5 stars.

Humana now has six Medicare Advantage contracts rated 4.5 stars and twelve rated four stars. The company also reported eleven more contracts rated four stars or higher than in the previous year. That represents a substantial improvement in the quality assessments attached to its insurance products.

The company highlighted operational improvements alongside the ratings. Compared with the prior year, Humana said 663,000 additional care opportunities were completed and 534,000 more members received annual preventive visits. These figures provide some supporting evidence that the ratings improvement was accompanied by changes in the services delivered to members.

There is an important distinction between the number of contracts and the number of people covered by them. The 95% figure refers to Humana's Medicare Advantage membership in qualifying contracts, not the proportion of all its contracts receiving high ratings. Large contracts can account for a substantial share of the company's members, making their individual ratings particularly consequential.

Why do Medicare Star Ratings matter financially?

CMS assigns Medicare Advantage plans ratings ranging from one to five stars. The system evaluates areas such as quality of care, member experience and customer service. The ratings help beneficiaries compare insurance options, but they also have direct financial consequences for insurers.

Under the Medicare Advantage payment framework, plans achieving at least four stars can become eligible for quality bonus payments. Ratings can also influence the rebates available to plans, affecting the resources that insurers can use to provide additional member benefits or support their economics.

The timing is important. According to the CMS 2027 Star Ratings fact sheet, the results published on October 8, 2026, will influence Medicare Advantage quality bonus payments in 2028.

That means the announcement improves visibility into a potentially important future revenue component. It does not mean Humana suddenly earned those additional payments during the current quarter.

This distinction is frequently overlooked when investors interpret operational announcements. A new contract, regulatory approval, reimbursement decision or quality certification can meaningfully change a company's future prospects without creating an immediate corresponding increase in earnings or cash flow.

Additional revenue is not automatically additional profit

Even when the bonus payments arrive, the relationship between revenue and profitability is not straightforward. Health insurers collect premiums and other payments, but a substantial portion of that revenue is required to cover medical services provided to members.

A useful metric in this industry is the medical benefit ratio, which measures the share of applicable premium revenue consumed by medical benefits. A higher ratio generally means more of the insurer's revenue is being spent on medical care, leaving less available to cover administrative expenses and generate operating profit.

In its second-quarter 2026 results, Humana reported an Insurance segment GAAP benefit ratio of 91.2%. Management also maintained its full-year Insurance segment benefit-ratio guidance of 92.75%, plus or minus 25 basis points.

Those figures illustrate the economic sensitivity of the business. When medical benefits consume more than ninety cents of each applicable premium dollar, relatively modest changes in medical costs can have a significant effect on the profitability remaining after other expenses.

The benefit ratio is not itself a profit margin, and the Insurance segment includes more than Medicare Advantage. It nevertheless provides useful context for understanding why higher revenue does not necessarily result in a proportionate increase in earnings.

Future quality bonuses could improve Humana's economics. But the company may also use some of the additional resources to provide more competitive member benefits, support enrollment or offset rising medical costs. The ultimate shareholder benefit depends on how those competing demands develop.

Strong regulatory performance does not automatically mean a strong investment

The latest MOATEY assessment provides a useful contrast to the regulatory announcement. Humana currently receives a Poor MOATEY rating, with an overall score of 28.2 out of 95 points and a No Grower classification.

MOATEY's five-year revenue growth measure stands at 10.59%, while its five-year earnings growth measure is negative at -17.73%. The framework currently awards Humana 4.5 of 15 available Growth points.

These observations do not contradict the improvement in CMS Star Ratings. They measure different things.

The CMS system evaluates the performance of Medicare insurance plans against healthcare quality and service criteria. MOATEY evaluates the underlying company using a systematic fundamental investment framework covering areas such as growth, financial health, management, competitive position and valuation.

In other words, a higher healthcare quality rating does not mechanically produce a higher investment rating.

MOATEY currently gives Humana the maximum 15 of 15 Financial Health points, but only 1 of 20 Moat points and 0 of 30 Valuation points. The combination demonstrates why examining the underlying components is more informative than interpreting any single score as a complete investment conclusion.

These are MOATEY framework observations, not forecasts of Humana's future financial performance. The framework's measures may include proprietary adjustments and should not automatically be interpreted as raw company-reported figures. The MOATEY factsheet and supporting documentation provide further information about the methodology and its historical validation.

Does a higher quality rating create a competitive advantage?

Higher Medicare Star Ratings may improve an insurer's competitive position by supporting its financial resources and making its plans more attractive to prospective members. Better service and health outcomes can also support customer relationships. However, these benefits do not automatically establish a durable competitive advantage.

That distinction matters because a sustainable economic moat generally requires an advantage that competitors find difficult to reproduce over time. A favorable quality rating can change as competitors improve, measurement thresholds evolve or operating performance weakens.

Humana's improvement therefore provides evidence of operational progress, but the long-term investment question remains whether that progress can be sustained while producing attractive returns on capital.

MOATEY's current moat assessment is relatively weak, at 1 of 20 points. Its Earnings Power Value is below its Net Reproduction Value, while the associated trend is classified as deteriorating. Those framework observations do not prove that Humana lacks every possible competitive advantage. They indicate that the current quantitative evidence provides limited support for a durable economic moat under MOATEY's assessment.

The most useful approach is to keep the operational achievement separate from the durability of its economic consequences.

The financial impact is still several steps away

Humana's new ratings provide greater visibility into its potential 2028 quality-related revenue. The company has also demonstrated meaningful progress in preventive care and member engagement. These are positive developments, but several intermediate steps still determine their eventual financial value.

Membership is one important variable. The number of members enrolled in qualifying contracts when the relevant payment calculations apply will affect the financial benefit. The annual Medicare enrollment period beginning October 15, 2026, will therefore provide additional information about customer demand and the distribution of members across plans.

Medical costs are another variable. Higher-quality plans may generate stronger revenue opportunities, but those opportunities can be offset if healthcare utilization or treatment costs rise more quickly than expected.

Finally, investors need to distinguish a temporary improvement in payment conditions from sustainable underlying profitability. A favorable bonus year can materially help earnings without necessarily changing the long-term economics of the insurance business.

That does not make the expected financial improvement unimportant. It simply means the value created by the ratings should be assessed through the future income statement and cash-flow statement rather than assumed from the announcement alone.

What long-term investors should watch next

The next stage of Humana's investment story is not simply whether its Medicare plans retain their improved Star Ratings. Investors should follow whether enrollment remains attractive, whether medical costs develop as expected and how management plans to use the additional financial resources associated with stronger quality performance.

The relationship between membership growth and margins will be particularly important. Growing an insurance business can increase revenue substantially, but the economic value depends on the profitability of the additional members rather than their number alone.

The same principle applies to the expected 2028 quality bonuses. The relevant question is not merely how much additional revenue becomes available. It is how much of that revenue ultimately contributes to sustainable earnings and free cash flow after medical benefits, operating expenses and other obligations.

Humana's latest announcement is a meaningful operational achievement. The company has improved an important external assessment of its insurance products, potentially strengthening its future revenue position.

For investors, however, the final test remains financial. A stronger operating indicator can improve the outlook for a business, but only durable economic results can establish how much value the improvement has actually created.